European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)

Recruiting

• Conditions: Non-Alcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver; Non-alcoholic Steatohepatitis

• Registration Number: NCT04190849
• Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Brief Summary

The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by relevant international specialists. This collaboration will build on existing infrastructure (local databases and bio-repositories) and will align with the adult European NAFLD Registry ("EPoS", Elucidating Pathways of Steatohepatitis study) to allow long-term follow-up supported by translational studies. Through an international, well-characterised large-scale cohort, we hope to: facilitate multi-centre clinical trials; extend our understanding of the key disease mechanisms of NAFLD; and establish the natural history of paediatric NAFLD.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-14
• Study First Submitted: 2019-12-05
• Study First Submitted QC: 2019-12-05
• Study First Posted: 2019-12-09
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-17
• Last Update Posted: 2022-03-04
• Primary Completion: 2047-11
• Study Completion: 2047-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Diagnosis made under 18 years of age.

• Diagnosis of NAFLD spectrum disease (simple steatosis (NAFL), steatosis with abnormal transaminases, NASH ± fibrosis or cirrhosis)

• Diagnosis established by:

  • Radiological evidence of hepatic steatosis (e.g. increased hepatic echogenicity on ultrasound), with
  • Exclusion of secondary causes (negative serological liver screen for HBV/HCV, caeruloplasmin >0.20g/L, no history of excess alcohol consumption, no evidence of iron overload, and no clinically significant alpha-1 antitrypsin (A1AT) phenotype (i.e. SZ, ZZ, SS), with or without
  • Histology (>5% steatosis and histology consistent with paediatric NAFLD)

Exclusion Criteria

• Secondary fatty liver disease (e.g. glycogen storage diseases, Wilson disease, viral hepatitis, drug-related, autoimmune hepatitis, type 1 diabetes mellitus)
• Post-transplant fatty liver
• >20g/day ethanol intake

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival	30-year follow-up	All-cause survival

Secondary Outcome Measures

Name	Time	Method
Cardiovascular morbidity	30-year follow-up	CAD, CVA, PAD
Liver morbidity	30-year follow-up	Decompensated liver disease, transplantation, HCC development
Asymptomatic progression of liver disease	30-year follow-up	Presence of advanced fibrosis (on biopsy or non-invasive imaging)

Trial Locations

Locations (3)

Maastricht UMC; 🇳🇱 Maastricht, Netherlands

Addenbrooke's Hospital; 🇬🇧 Cambridge, Cambridgeshire, United Kingdom

Birmingham Children's Hospital; 🇬🇧 Birmingham, United Kingdom